Medical Psilocybin

Psychedelic Science and Medicine News Roundup: March 1-12

Share on facebook
Share on twitter
Share on linkedin
Share on email

With each passing week, we are seeing more and more advances in psychedelic research in the scientific and medical fields. Truffle Report has compiled a roundup of major medical and scientific news from the first two weeks of March 2021, making it easier for you to track these ongoing developments.

Innovators Identify Crucial Advancements to Uncover Medical Breakthroughs From Psychedelics

March 2, 2021 – Mind Medicine, Numinus Wellness, Field Trip Health, and Cybin Inc. have all announced clinical research trials that are either planned or are already underway for medicinal psychedelics. MINDCURE also got involved in clinical psychedelic research by partnering with ATMA Journey Centers Inc.

Positive Effects of Psychedelic Microdosing Likely Due to Placebo Effect, Study Finds

March 3, 2021 – A study published in eLife details the results of the largest placebo-controlled trial evaluating the effects of psychedelics to date. The researchers concluded that the psychological benefits of microdoses of psychedelics could be due to the placebo effect and not the substances themselves.

Psychedelic Science Holds Promise for Mainstream Medicine

March 10, 2021 – A team of neuroscientists from the University of Nevada in Las Vegas is studying how psychedelics affect brain activity. Recent research in rodents shows a strong connection between brain activity and behaviours resulting from psychedelic treatment. This could be a step forward in the quest to better understand psychedelics’ potential therapeutic effects and uses. 

See Also
DiPT Auditory Hallucinations Graphic

Microdose Announces the Launch of Accredited Course Series “The Science of Psychedelics: Training for Medical Professionals”

March 10, 2021 – Microdose announced “The Science of Psychedelics: Training for Medical Professionals”, which is an online, accredited course series for physicians, psychologists, social workers, mental health counselors, pharmacists, and other medical professionals. The course has been approved for 8.0 AMA PRA Category 1 Credits™ through the joint providership of CME Consultants and MD Media Inc., as well as accreditation through the American Psychological Association (APA), the California Board of Registered Nursing, the California Board of Behavioral Sciences, and the Oregon Board of Naturopathic Medicine (OBNM).

The @US_FDA has granted IND authorization to @CybinInc to conduct a study measuring the cerebral cortex hemodynamics of #ketamine using @KernelCo's flow headset.

Read the full story here: http://ow.ly/vW0J50GzzAP

#psychedelics #neuroscience #tech #brains

Are you planning to have an experience with #5MeO-#DMT?

Consider signing up for The 5-MeO-DMT Survey to help the team at @Imperial_PRG learn more about the effects of this fascinating molecule!

#5MeODMT

https://5meodmt.psychedelicsurvey.com/

Load More...

Related Articles

Scroll To Top